Skip to main content
Fig. 4 | Skeletal Muscle

Fig. 4

From: Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle

Fig. 4

Effect of pharmacological modulation of muscle excitability (salbutamol, 9AC, mexiletine) in the TA muscle from mdx mice. a Force drop following lengthening contractions in mdx mice treated with salbutamol. b Maximal force before lengthening contractions (initial) in mdx mice treated with salbutamol. c Force drop following nine lengthening contractions in mdx mice treated with anthracene-9-carboxylic acid (9AC). d CMAP (RMS) during 125 Hz stimulation in mdx mice treated with mexiletine, before lengthening contractions. e Force and CMAP (RMS) drops following lengthening contractions in mdx mice treated with mexiletine. f Maximal force before lengthening contractions in mdx mice treated with mexiletine. CMAP compound muscle action potential, Mdx + Salbu mdx mice treated with salbutamol, Mdx + 9AC mdx mice treated with 9AC, Mdx + Mexi mdx mice treated with mexiletine, Mdx LC lengthening contractions in mdx mice, a significantly different from before lengthening contractions (p < 0.05), c significant difference with non-treated mice (p < 0.05). n = 6–15 per group

Back to article page

Skeletal Muscle

ISSN: 2044-5040

Contact us